---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-006781"
form_type: "8-K"
ticker: "ADMA"
cik: "0001368514"
company_name: "ADMA BIOLOGICS, INC."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:10:32.588584+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ADMA Biologics reports record FY2025 revenue $510M (+20%), Adj. EBITDA $231M (+40%); CFO transition to Kohler

## Summary
- FY2025 total revenue $510.2M (+20% YoY); ASCENIV revenue $363M (+51% YoY). Gross margin 57.4% vs 51.5%.
- GAAP net income $146.9M (FY2024: $197.7M incl. $84.3M tax benefit). Adjusted net income $160.8M (+35% YoY). Adjusted EBITDA $231M (+40%).
- FY2026 guidance: revenue >$635M, Adj. net income >$255M, Adj. EBITDA >$360M. Targeting >$1.1B revenue by FY2029.
- CFO Brad Tade retiring effective Feb 25, 2026; succeeded by Terry Kohler (ex-CFO of OptiNose, Verrica). Kohler will become CFO/Treasurer Feb 26.
- Q4 2025: revenue $139.2M (+18% YoY); GAAP net income $49.4M; Adj. EBITDA $73.6M (+52% YoY).

## SEC filing metadata
- accession: 0001140361-26-006781
- form_type: 8-K
- ticker: ADMA
- cik: 0001368514
- company_name: ADMA BIOLOGICS, INC.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1368514/000114036126006781/0001140361-26-006781-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1368514/000114036126006781/ef20066393_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-006781
- JSON: https://secwatch.observer/filing/0001140361-26-006781.json
- Plain text: https://secwatch.observer/filing/0001140361-26-006781.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.